Aktis Oncology, Inc.
$16.15-$0.25 (-1.5%)
Last close · Data as of Nov 20, 2026
- Market cap
- $1.1B
- P/E
- -17.3x
- EV / EBITDA
- -14.8x
- Revenue
- $6.5M
- Net margin
- -980.9%
- ROCE
- -32.0%
Price chart
Technical chartScreen technicals →A period is left blank when the price history is shorter than the period.
Daily closes.
Go deeper
Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes
Performance
Price return, before dividends, to the 20 Nov 2026 close.
- 1M
- +0.4%
- 3M
- -32.7%
- 6M
- -15.1%
- 1Y
- Short history
- 5Y
- Short history
- A period is left blank when the price history is shorter than the period.
52-week range
Day change -$0.25 (-1.5%) from $16 to $16 · Last close Nov 20, 2026
News & filings
What Aktis Oncology filed, who traded, and what's next
How to read this
"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.
AI Summary
US StockConcernShareholders' equity is negative: liabilities exceed assets.
Strengths (1)
- Revenue more than doubled in fiscal 2025.
- The stored ratios (as of 11 Jun 2026) describe a profitable period while fiscal 2025 shows a net loss: the two cover different periods, so the ratio points are not shown.
- Shareholders' equity is negative, so return on equity and debt to equity are not shown.
Prices to the 20 Nov 2026 close · Financial year: fiscal 2025
Rule-based from financial data. Not advice.
About the company
Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers.
Read moreShow less
Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers. The company's lead product candidate includes [225Ac]Ac-AKY-1189, a miniprotein radioconjugate platform which is in ongoing Phase 1b clinical trial for the treatment of Nectin-4 expressing solid tumors, including locally advanced or metastatic urothelial cancer, breast cancer, NSCLC, colorectal cancer and cervical cancer; and [225Ac]Ac-AKY-2519 to deliver 225Ac to B7-H3 (CD276) expressing tumors, including prostate, lung and other solid tumors. It has license and collaboration agreements with Protein Innovation, Inc., TRIUMF Innovations, Inc., and Eli Lilly. The company was formerly known as HotKnot Therapeutics, Inc. and changed its name to Aktis Oncology, Inc. in April 2020. Aktis Oncology, Inc. was incorporated in 2020 and is headquartered in Boston, Massachusetts.
- Sector
- Healthcare
- Shares outstanding
- 52.5M
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- $1.1B
- P/E
- -17.3x
- P/B
- -7.5x
- EV / EBITDA
- -14.8x
- EV / Sales
- 165.2x
- P/S
- 169.2x
- 52-week high
- $32.23
- 52-week low
- $14.59
Profitability
- Operating margin
- -1149.5%
- Net margin
- -980.9%
- EBITDA margin
- -1113.7%
- ROE
- 43.6%
- ROCE
- -32.0%
- ROA
- -24.1%
- Asset turnover
- 0.02
Growth
- RevenueFY2025, the latest fiscal year in the company's growth history.
- $6.5M
- Revenue growth, 1YFY2025, the latest fiscal year in the company's growth history.
- 336.9%
- Net profit growth, 1YFY2025, the latest fiscal year in the company's growth history.
- 44.9%
- Free cash flowFY2025, the latest fiscal year in the company's growth history.
- -$73.7M
Solvency
- Current ratio
- 7.37
- Debt / Equity
- -0.08
- Debt / Assets
- 0.04
- CFO / Net profit
- 1.01
- Cash / Market cap
- 3.4%
Where the revenue went
FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.
| Line | FY2025 |
|---|---|
| Revenue | $6.5M |
| Gross profit | $6.5M |
| Operating expenses | $81.2M |
| Research and development | $67.5M |
| Selling, general and administrative | $12.6M |
| Operating income | -$74.7M |
| Interest and other | $11.0M |
| Pretax income | -$63.7M |
| Tax and other | $0.00 |
| Net income | -$63.7M |
Revenue and net profit
Revenue grew 336.9% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2022 | $0.00 | -$17.9M |
| FY2023 | $0.00 | -$28.6M |
| FY2024 | $1.5M | -$44.0M |
| FY2025 | $6.5M | -$63.7M |
Cash flows
FY2025: -$64.1M from operations, -$73.7M free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2022 | -$18.1M | -$20.4M |
| FY2023 | -$30.0M | -$33.8M |
| FY2024 | $14.8M | $11.9M |
| FY2025 | -$64.1M | -$73.7M |
Growth
Latest fiscal year 2025: each figure with its change over the year before.
- Revenue
- $6.5M+336.9%1Y
- EBITDA
- -$72.4M
- Net profit
- -$63.7M
- Cash from operations
- -$64.1M-534.4%1Y
- Free cash flow
- -$73.7M-719.4%1Y
| Year | Revenue | EBITDA | Net profit | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|
| FY2025 | $6.5M | -$72.4M | -$63.7M | -$73.7M | 43.6% | +336.9% | +44.9% |
Monthly returns
Month-by-month returns of AKTS across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Assets | $264.9M |
| Current assets | $230.3M |
| Non-current assets | $34.6M |
| Liabilities | $411.0M |
| Current liabilities | $31.2M |
| Non-current liabilities | $379.8M |
| Equity | -$146.2M |
| Paid-in capital | $10.4M |
| Retained earnings | -$156.6M |
Market cap against peers
8 peers: same sector, nearest by size.
Peers map
Healthcare companies placed by value, growth and quality; AKTS highlighted.
P/E against peers
Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.
Not shown (no positive earnings and no EV / Sales): Savara Inc.
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Aktis Oncology, Inc.AKTSthis company | $1.1B | -17.3x | -7.5x | 43.6% | -14.8x |
| Absci CorporationABSI | $1.1B | -9.9x | 6.0x | -60.8% | -10.9x |
| OPKO Health, Inc.OPK | $1.1B | -4.9x | 0.9x | -17.8% | -27.4x |
| MannKind CorporationMNKD | $1.1B | 185.5x | -21.3x | -11.5% | 26.8x |
| Savara Inc.SVRA | $1.1B | -9.1x | 5.3x | -58.5% | -8.8x |
| Omada Health, Inc.OMDA | $1.1B | -84.7x | 4.7x | -5.6% | -181.0x |
| Xeris Biopharma Holdings, Inc.XERS | $1.1B | 1916.5x | 77.6x | 4.0% | 28.6x |
| Collegium Pharmaceutical, Inc.COLL | $1.1B | 16.9x | 3.5x | 20.8% | 4.1x |
| CONMED CorporationCNMD | $1.1B | 22.5x | 1.0x | 4.6% | 10.5x |
| Peer median | — | 6.0x | 4.1x | -8.5% | -2.4x |
Year-to-date ROI
AKTS since 1 January, against earlier years.
Historical volatility
AKTS's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.
Consolidated figures in USD, fiscal years, newest first.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2024 | -3493.3% |
| FY2025 | -1148.9% |
| Line | FY2025 |
|---|---|
| RevenueTotal Revenue | $6.5M |
| Operating expensesOperating Expense | $81.2M |
| Research and developmentResearch And Development | $67.5M |
| Selling, general and administrativeSelling General And Administration | $12.6M |
| Depreciation and amortisationDepreciation And Amortization In Income Statement | $1.1M |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion Income Statement | $1.1M |
| Depreciation income statementDepreciation Income Statement | $1.1M |
| Total expensesTotal Expenses | $81.2M |
| Operating incomeOperating Income | -$74.7M |
| Interest and other | |
| Pretax incomePretax Income | -$63.7M |
| Tax | |
| Net incomeNet Income | -$63.7M |
| Per share | |
| Supplementary |
| Line | FY2025 |
|---|---|
| AssetsTotal Assets | $264.9M |
| Current assetsCurrent Assets | $230.3M |
| Non-current assetsTotal Non Current Assets | $34.6M |
| LiabilitiesTotal Liabilities Net Minority Interest | $411.0M |
| Current liabilitiesCurrent Liabilities | $31.2M |
| Non-current liabilitiesTotal Non Current Liabilities Net Minority Interest | $379.8M |
| EquityTotal Equity Gross Minority Interest | -$146.2M |
| Supplementary |
| Line | FY2025 |
|---|---|
| Operating cash flowOperating Cash Flow | -$64.1M |
| Cash from continuing operationsCash Flow From Continuing Operating Activities | -$64.1M |
| Net income, continuing operationsNet Income From Continuing Operations | -$63.7M |
| Depreciation and amortisationDepreciation And Amortization | $2.3M |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion | $2.3M |
| Amortization of securitiesAmortization Of Securities | -$4.6M |
| Stock-based compensationStock Based Compensation | $5.1M |
| Operating gains and lossesOperating Gains Losses | — |
| Gain loss on investment securitiesGain Loss On Investment Securities | — |
| Change in working capitalChange In Working Capital | -$3.2M |
| Investing cash flowInvesting Cash Flow | $66.0M |
| Cash from continuing investingCash Flow From Continuing Investing Activities | $66.0M |
| Capital expenditureCapital Expenditure | -$9.6M |
| Purchase of PP&EPurchase Of PPE | -$9.6M |
| Sale of PP&ESale Of PPE | — |
| Net PP&E purchases and salesNet PPE Purchase And Sale | -$9.6M |
| Purchase of investmentsPurchase Of Investment | -$193.9M |
| Sale of investmentsSale Of Investment | $269.4M |
| Net investment purchases and salesNet Investment Purchase And Sale | $75.5M |
| Financing cash flowFinancing Cash Flow | -$1.2M |
| Cash from continuing financingCash Flow From Continuing Financing Activities | -$1.2M |
| Shares issuedIssuance Of Capital Stock | $0.00 |
| Stock options exercisedProceeds From Stock Option Exercised | $340.0k |
| Preferred stock issuancePreferred Stock Issuance | $0.00 |
| Net preferred stock issuanceNet Preferred Stock Issuance | $0.00 |
| Other financing chargesNet Other Financing Charges | -$1.6M |
| Change in cashChanges In Cash | $620.0k |
| Cash at the start of the yearBeginning Cash Position | $38.3M |
| Cash at the end of the yearEnd Cash Position | $38.9M |
| Free cash flowFree Cash Flow | -$73.7M |
Learn while you research
Academy chapters picked for Aktis Oncology, Inc. and the metrics on this page.
- 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 02 Growth Investing337% revenue growth is in the top tier, learn how to value growth.7 min read
- 03 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
- 04 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 05 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
- 06 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read